The Breast Cancer Program was established in 1994 and has been led by Lewis Chodosh, MD, PhD and Angela DeMichele, MD, MSCE since 2005. Members of the Breast Cancer Program are focused on understanding the underlying causes of breast cancer to improve the detection, prevention and treatment of this disease. Program members work to achieve this goal by focusing on four key thematic areas: 1) Elucidation of the molecular mechanisms of breast cancer development and progression; 2) Improvements in genetic risk assessment and development of novel prevention strategies; 3) Development of novel imaging approaches to improve breast cancer detection and the assessment of therapeutic response; and 4) Translation of laboratory discoveries to novel therapeutics and biomarkers of response/outcome. These scientific goals are accomplished through four thematic groups: Breast Cancer Biology, Cancer Risk Evaluation and Prevention, Breast Imaging, and Therapeutics and Biomarkers. Members are highly interactive, as reflected in their leadership of four collaborative grants, including two NCI UOIs, an NCI U24, and a Department of Defense Breast Cancer Center of Excellence. In addition to facilitating intra- and interprogrammatic collaborations, program leadership has emphasized breast cancer clinical research as a major focus, recruited external faculty who bring important new expertise to the Program, and participated in major ACC retreats that emphasize breast cancer research. The ACC's investment in clinical/clinical research efforts, particularly the Rena Rowan Breast Center, has facilitated patient-oriented research. The Breast Cancer Program consists of 16 faculty members from seven departments in the School of Medicine and School of Arts and Sciences. These members have $8,513,166 in cancer-related grant funding (annual direct costs), of which $7,729,386 is peer-reviewed and $2,510,558 is NCI-funded. During the last funding period, members of the Breast Cancer Program published 390 cancer-related papers, of which 11% were the result of intra-programmatic collaborations and 42% were the result of inter-programmatic collaborations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016520-39
Application #
8823502
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-12-01
Budget End
2015-11-30
Support Year
39
Fiscal Year
2015
Total Cost
$113,546
Indirect Cost
$85,970
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Huang, Mo; Wang, Jingshu; Torre, Eduardo et al. (2018) SAVER: gene expression recovery for single-cell RNA sequencing. Nat Methods 15:539-542
Yam, Clinton; Xu, Xiaowei; Davies, Michael A et al. (2018) A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clin Cancer Res 24:22-32
Onorati, Angelique V; Dyczynski, Matheus; Ojha, Rani et al. (2018) Targeting autophagy in cancer. Cancer 124:3307-3318
Rebecca, Vito W; Nicastri, Michael C; Fennelly, Colin et al. (2018) PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discov :
Garfall, Alfred L; Stadtmauer, Edward A; Hwang, Wei-Ting et al. (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3:
Jang, Jeong Hoon; Manatunga, Amita K; Taylor, Andrew T et al. (2018) Overall indices for assessing agreement among multiple raters. Stat Med 37:4200-4215
Scheel, John R; Kim, Eunhee; Partridge, Savannah C et al. (2018) MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. AJR Am J Roentgenol 210:1376-1385
Romero, Sally A D; Brown, Justin C; Bauml, Joshua M et al. (2018) Barriers to physical activity: a study of academic and community cancer survivors with pain. J Cancer Surviv 12:744-752
Hinderer, Christian; Katz, Nathan; Buza, Elizabeth L et al. (2018) Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther 29:285-298
Li, Jinyang; Byrne, Katelyn T; Yan, Fangxue et al. (2018) Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49:178-193.e7

Showing the most recent 10 out of 1047 publications